Sign In
Buy NMRA
$1.62
+0.105 (+6.95%)
At Close: Jun 26, 2026
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
11:00am, Thursday, 18'th Jun 2026
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOAST
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
10:05am, Thursday, 18'th Jun 2026
NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOAST
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significan
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
11:15am, Tuesday, 16'th Jun 2026
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
12:47pm, Monday, 15'th Jun 2026
Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significan
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
12:46pm, Monday, 15'th Jun 2026
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) complied with federal securities
Neumora Therapeutics scraps depression drug after two late-stage trial failures
08:13am, Monday, 15'th Jun 2026
Neumora Therapeutics said on Monday it would stop developing its depression drug after two late-stage trials failed to meet their main goals.
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
08:00am, Monday, 15'th Jun 2026
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease a
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
04:05pm, Tuesday, 12'th May 2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 07'th May 2026
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
07:00am, Monday, 06'th Apr 2026
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that tar
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
02:04pm, Wednesday, 01'st Apr 2026
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeu
Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)
02:31am, Tuesday, 31'st Mar 2026
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) was the target of some unusual options trading activity on Monday. Stock traders acquired 2,812 call options on the company. This is an incr
Neumora Therapeutics: Downgrading After Navacaprant Development Setback
04:13pm, Monday, 30'th Mar 2026
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollme
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
11:22am, Monday, 30'th Mar 2026
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
